Ocean Biomedical deploys capital and development expertise to move discoveries from universities and medical centers into the clinic, operating a discovery-to-clinic platform focused on oncology, pulmonary fibrosis and infectious disease (notably malaria). The company is developing five initial discoveries and has disclosed novel targets and approaches including CHI3L1 bispecific antibodies for cancer, Chit1 and OCF-203 for pulmonary fibrosis, and parasite targets PfSEA-1, PfGARP and PfCDPK-5 for malaria. Ocean partners with scientists at institutions such as Brown and Stanford and has secured patent activity and presentations at NIH and scientific meetings. Management says the company will use recent financings to strengthen its capital position and accelerate IND-enabling studies and IND filings for its lead programs. Ocean is a public company (NASDAQ: OCEA) and highlights a growing institutional and retail investor base alongside non-dilutive grant support. The company emphasizes that its discoveries to date are based on laboratory and animal studies and that clinical efficacy and safety in humans remain to be demonstrated.

Total raised

$59M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2023